NZ590658A - Glutaminyl cyclase as a diagnostic / prognostic indicator for neurodegenerative diseases - Google Patents

Glutaminyl cyclase as a diagnostic / prognostic indicator for neurodegenerative diseases

Info

Publication number
NZ590658A
NZ590658A NZ590658A NZ59065809A NZ590658A NZ 590658 A NZ590658 A NZ 590658A NZ 590658 A NZ590658 A NZ 590658A NZ 59065809 A NZ59065809 A NZ 59065809A NZ 590658 A NZ590658 A NZ 590658A
Authority
NZ
New Zealand
Prior art keywords
amount
biological sample
detected
nds
mci
Prior art date
Application number
NZ590658A
Other languages
English (en)
Inventor
Hans-Ulrich Demuth
Stephan Schilling
Martin Kleinschmidt
Jens-Ulrich Rahfeld
Astrid Kehlen
Monique Bornack
Original Assignee
Probiodrug Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41256108&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ590658(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Probiodrug Ag filed Critical Probiodrug Ag
Publication of NZ590658A publication Critical patent/NZ590658A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88Lyases (4.)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4703Regulators; Modulating activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/521Chemokines
    • G01N2333/523Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/91045Acyltransferases (2.3)
    • G01N2333/91074Aminoacyltransferases (general) (2.3.2)
    • G01N2333/9108Aminoacyltransferases (general) (2.3.2) with definite EC number (2.3.2.-)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/38Pediatrics
    • G01N2800/385Congenital anomalies
    • G01N2800/387Down syndrome; Trisomy 18; Trisomy 13

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ590658A 2008-07-31 2009-07-31 Glutaminyl cyclase as a diagnostic / prognostic indicator for neurodegenerative diseases NZ590658A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8515408P 2008-07-31 2008-07-31
PCT/EP2009/059951 WO2010012828A2 (en) 2008-07-31 2009-07-31 Glutaminyl cyclase as a diagnostic / prognostic indicator for neurodegenerative diseases

Publications (1)

Publication Number Publication Date
NZ590658A true NZ590658A (en) 2012-07-27

Family

ID=41256108

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ590658A NZ590658A (en) 2008-07-31 2009-07-31 Glutaminyl cyclase as a diagnostic / prognostic indicator for neurodegenerative diseases

Country Status (15)

Country Link
US (3) US20100028918A1 (https=)
EP (1) EP2329274B1 (https=)
JP (1) JP5677297B2 (https=)
KR (1) KR101682728B1 (https=)
CN (2) CN103983787A (https=)
AU (1) AU2009275869B2 (https=)
BR (1) BRPI0916601B1 (https=)
CA (1) CA2731933A1 (https=)
EA (1) EA025107B1 (https=)
IL (1) IL210266A (https=)
MX (1) MX2011001093A (https=)
NZ (1) NZ590658A (https=)
SG (1) SG193148A1 (https=)
WO (1) WO2010012828A2 (https=)
ZA (1) ZA201100177B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011101433A1 (en) * 2010-02-18 2011-08-25 Probiodrug Ag Methods of diagnosing inflammatory diseases by determining pyroglutamate-modified mcp-1 and screening methods for inhibitors of glutaminyl cyclase
SG194770A1 (en) 2011-05-27 2013-12-30 Probiodrug Ag Radiolabelled glutaminyl cyclase inhibitors
JP2018501482A (ja) 2014-12-19 2018-01-18 プロビオドルグ エージー pGlu−Abetaペプチドの検出のための新規の方法
CN104946680A (zh) * 2015-06-11 2015-09-30 深圳大学 用于表达qc的重组载体及其制备方法、引物、基因工程菌
KR102362919B1 (ko) * 2016-07-08 2022-02-16 아지노모토 가부시키가이샤 경도 인지 장해 또는 알츠하이머형 인지증의 평가 방법
KR102858457B1 (ko) * 2023-06-07 2025-09-11 계명대학교 산학협력단 Ccl8 단백질 또는 이를 코딩하는 유전자를 유효성분으로 포함하는 퇴행성 뇌질환 진단용 바이오마커 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4374316B2 (ja) * 1993-01-25 2009-12-02 武田薬品工業株式会社 β−アミロイドまたはその誘導体に対する抗体およびその用途
JP3590468B2 (ja) * 1996-01-22 2004-11-17 財団法人 東京都医学研究機構 アルツハイマー病診断薬
WO2004013172A2 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
US7732162B2 (en) * 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
CN1784220B (zh) * 2003-05-05 2011-08-03 前体生物药物股份公司 谷氨酰胺酰基和谷氨酸环化酶效应物的应用
BRPI0415409A (pt) * 2003-10-15 2006-12-05 Probiodrug Ag uso de efetuadores de ciclases de glutaminila e glutamato
US20060094064A1 (en) * 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
CA2554809C (en) * 2004-02-05 2014-04-29 Probiodrug Ag Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase
US7592467B2 (en) * 2005-04-11 2009-09-22 Probiodrug Ag Inhibitors of prolyl endopeptidase
EP1865326B1 (en) * 2006-06-08 2011-09-07 FU Berlin Assay for the diagnosis of Alzheimer's Disease based on the determination of the ratio of secretase Aß cleavage products
EA016584B1 (ru) * 2006-09-21 2012-06-29 Пробиодруг Аг Новые гены, родственные гену глутаминилциклазы
WO2008087197A1 (en) * 2007-01-19 2008-07-24 Probiodrug Ag In vivo screening models for treatment of alzheimer's disease and other qpct-related disorders

Also Published As

Publication number Publication date
CN102112880A (zh) 2011-06-29
EP2329274B1 (en) 2015-12-02
IL210266A (en) 2016-04-21
ZA201100177B (en) 2012-02-29
CN102112880B (zh) 2014-06-25
US20150247180A1 (en) 2015-09-03
BRPI0916601B1 (pt) 2021-05-25
HK1155813A1 (en) 2012-05-25
WO2010012828A2 (en) 2010-02-04
JP5677297B2 (ja) 2015-02-25
SG193148A1 (en) 2013-09-30
BRPI0916601A2 (pt) 2015-11-10
US20170097365A1 (en) 2017-04-06
MX2011001093A (es) 2011-03-15
CN103983787A (zh) 2014-08-13
AU2009275869A1 (en) 2010-02-04
EP2329274A2 (en) 2011-06-08
EA201100253A1 (ru) 2011-10-31
WO2010012828A3 (en) 2010-05-06
KR20110049781A (ko) 2011-05-12
IL210266A0 (en) 2011-03-31
JP2011529571A (ja) 2011-12-08
KR101682728B1 (ko) 2016-12-05
AU2009275869B2 (en) 2015-05-21
EA025107B1 (ru) 2016-11-30
CA2731933A1 (en) 2010-02-04
US20100028918A1 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
US20170097365A1 (en) Glutaminyl cyclase as a diagnostic/prognostic indicator for neurodegenerative diseases
Pera et al. Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease
RU2461837C2 (ru) Высокочувствительные иммуноанализы и наборы для определения представляющих интерес пептидов и белков
EP2504356A1 (en) Novel diagnostic method for the diagnosis of alzheimer's disease or mild cognitive impairment
JP5755149B2 (ja) 方法
TW201131167A (en) Methods and reagents for improved detection of amyloid beta peptides
CN112858685A (zh) 一种神经退行性疾病标志物β-spectrin及其应用
JP2012530253A (ja) ペルオキシレドキシン4の診断的使用
KR20220112204A (ko) 뇌의 레닌-안지오텐신 시스템 인자를 이용한 알츠하이머병의 진단 방법
WO2008031190A1 (en) Alpha-1-antitrypsin as a diagnostic/prognostic indicator for neurodegenerative diseases
El Mouedden et al. Development of a specific ELISA for the quantitative study of amino-terminally truncated beta-amyloid peptides
US20170030929A1 (en) Diagnosis of chronic kidney disease by quantitative analysis of post-translational modifications of plasma proteins
HK1197762A (en) Glutaminyl cyclase as a diagnostic / prognostic indicator for neurodegenerative diseases
HK1155813B (en) Glutaminyl cyclase as a diagnostic / prognostic indicator for neurodegenerative diseases
Magini et al. Fibroblasts from PS1 mutated pre-symptomatic subjects and Alzheimer's disease patients share a unique protein levels profile
JP2014070037A (ja) アルツハイマー病の診断薬および診断方法

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 31 JUL 2016 BY PAVIS EG

Effective date: 20130719

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JUL 2017 BY PAVIS EG

Effective date: 20160722

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JUL 2018 BY PAVIS GMBH

Effective date: 20170721

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JUL 2019 BY PAVIS GMBH

Effective date: 20180720

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JUL 2020 BY PAVIS GMBH

Effective date: 20190717

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JUL 2021 BY PAVIS PAYMENTS GMBH

Effective date: 20200724

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JUL 2022 BY PAVIS PAYMENTS GMBH

Effective date: 20210721

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JUL 2023 BY PAVIS PAYMENTS GMBH

Effective date: 20220720

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JUL 2024 BY PAVIS PAYMENTS GMBH

Effective date: 20230718

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JUL 2025 BY PAVIS PAYMENTS GMBH

Effective date: 20240715

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JUL 2026 BY PAVIS PAYMENT GMBH

Effective date: 20250718